{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T15:53:47Z","timestamp":1790351627902,"version":"4.1.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 GM118553"],"award-info":[{"award-number":["R01 GM118553"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Influenza viruses infect millions of humans every year causing an estimated 400,000 deaths globally. Due to continuous virus evolution current vaccines provide only limited protection against the flu. Several antiviral drugs are available to treat influenza infection, and one of the most commonly used drugs is oseltamivir (Tamiflu). While the mechanism of action of oseltamivir as a neuraminidase inhibitor is well-understood, the impact of oseltamivir on influenza virus dynamics in humans has been controversial. Many clinical trials with oseltamivir have been done by pharmaceutical companies such as Roche but the results of these trials until recently have been provided as summary reports or papers. Typically, such reports included median virus shedding curves for placebo and drug-treated influenza virus infected volunteers often indicating high efficacy of the early treatment. However, median shedding curves may be not accurately representing drug impact in individual volunteers. Importantly, due to public pressure clinical trials data testing oseltamivir efficacy has been recently released in the form of redacted PDF documents. We digitized and re-analyzed experimental data on influenza virus shedding in human volunteers from three previously published trials: on influenza A (1 trial) or B viruses (2 trials). Given that not all volunteers exposed to influenza viruses actually start virus shedding we found that impact of oseltamivir on the virus shedding dynamics was dependent on (i) selection of volunteers that were infected with the virus, and (ii) the detection limit in the measurement assay; both of these details were not well-articulated in the published studies. By assuming that any non-zero viral measurement is above the limit of detection we could match previously published data on median influenza A virus (flu A study) shedding but not on influenza B virus shedding (flu B study B) in human volunteers. Additional analyses confirmed that oseltamivir had an impact on the duration of shedding and overall shedding (defined as area under the curve) but this result varied by the trial. Interestingly, treatment had no impact on the rates at which shedding increased or declined with time in individual volunteers. Additional analyses showed that oseltamivir impacted the kinetics of the end of viral shedding, and in about 20\u201340% of volunteers that shed the virus treatment had no impact on viral shedding duration. Our results suggest an unusual impact of oseltamivir on influenza viruses shedding kinetics and caution about the use of published median data or data from a few individuals for inferences. Furthermore, we call for the need to publish raw data from critical clinical trials that can be independently analyzed.<\/jats:p>","DOI":"10.3389\/fmicb.2021.631211","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:52:08Z","timestamp":1614559928000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Impact of Oseltamivir Treatment on Influenza A and B Virus Dynamics in Human Volunteers"],"prefix":"10.3389","volume":"12","author":[{"given":"Kyla L.","family":"Hooker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vitaly V.","family":"Ganusov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1002\/jmv.24566","article-title":"Characterization of influenza activity based on virological surveillance of influenza-like illness in tropical singapore, 2010-2014","volume":"88","author":"Ang","year":"2016","journal-title":"J. Med. Virol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"7590","DOI":"10.1128\/JVI.01623-05","article-title":"Kinetics of influenza a virus infection in humans","volume":"80","author":"Baccam","year":"2006","journal-title":"J. Virol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijid.2016.05.013","article-title":"Randomized controlled trials for influenza drugs and vaccines: a review of controlled human infection studies","volume":"49","author":"Balasingam","year":"2016","journal-title":"Int. J. Infect. Dis"},{"key":"B4","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1473-3099(07)70029-4","article-title":"Transmission of influenza a in human beings","volume":"7","author":"Brankston","year":"2007","journal-title":"Lancet Infect. Dis"},{"key":"B5","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1214\/ss\/1009213286","article-title":"Interval estimation for a binomial proportion","volume":"16","author":"Brown","year":"2001","journal-title":"Stat. Sci"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e1003568","DOI":"10.1371\/journal.pcbi.1003568","article-title":"Impact of different oseltamivir regimens on treating influenza a virus infection and resistance emergence: insights from a modelling study","volume":"10","author":"Canini","year":"2014","journal-title":"PLoS Comput. Biol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"38749","DOI":"10.1038\/srep38749","article-title":"Heterogeneous shedding of influenza by human subjects and its implications for epidemiology and control","volume":"6","author":"Canini","year":"2016","journal-title":"Sci. Rep"},{"key":"B8","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/infdis\/jiv058","article-title":"Association of oseltamivir treatment with virus shedding, illness, and household transmission of influenza viruses","volume":"212","author":"Cheung","year":"2015","journal-title":"J. Infect. Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e00797","DOI":"10.1128\/JVI.00797-19","article-title":"Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs","volume":"93","author":"Dhakal","year":"2019","journal-title":"J. Virol"},{"key":"B10","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-4541-9","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1993"},{"key":"B11","doi-asserted-by":"publisher","first-page":"7181","DOI":"10.1007\/s00253-016-7542-4","article-title":"Influenza virus intracellular replication dynamics, release kinetics, and particle morphology during propagation in mdck cells","volume":"100","author":"Frensing","year":"2016","journal-title":"Appl. Microbiol. Biotechnol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fmicb.2016.01131","article-title":"Strong inference in mathematical modeling: a method for robust science in the twenty-first century","volume":"7","author":"Ganusov","year":"2016","journal-title":"Front. Microbiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3390\/v10030099","article-title":"Time intervals in sequence sampling, not data modifications, have a major impact on estimates of HIV escape rates","volume":"10","author":"Ganusov","year":"2018","journal-title":"Viruses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"P01010","DOI":"10.1088\/1742-5468\/2013\/01\/P01010","article-title":"Modeling HIV escape from cytotoxic T lymphocyte responses","volume":"2013","author":"Ganusov","year":"2013","journal-title":"J. Stat. Mech"},{"key":"B15","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-3-030-57204-4_10","article-title":"\u201cExperimental and mathematical approaches to quantify recirculation kinetics of lymphocytes,\u201d","volume-title":"Mathematical, Computational and Experimental T Cell Immunology","author":"Ganusov","year":"2021"},{"key":"B16","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1098\/rsif.2009.0067","article-title":"Towards a quantitative understanding of the within-host dynamics of influenza a infections","volume":"7","author":"Handel","year":"2010","journal-title":"J. R. Soc. Interface"},{"key":"B17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1177\/135965350000500305","article-title":"Oral oseltamivir in human experimental influenza b infection","volume":"5","author":"Hayden","year":"2000","journal-title":"Antiviral Therapy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1056\/NEJMoa1716197","article-title":"Baloxavir marboxil for uncomplicated influenza in adults and adolescents","volume":"379","author":"Hayden","year":"2018","journal-title":"N. Engl. J. Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1001\/jama.282.13.1240","article-title":"Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment","volume":"282","author":"Hayden","year":"1999","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001265","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults","author":"Jefferson","year":"2000","journal-title":"Cochrane Datab. Syst. Rev"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008965.pub4","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children","author":"Jefferson","year":"2014","journal-title":"Cochrane Datab. Syst. Rev"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001265.pub2","article-title":"Neuraminidase inhibitors for preventing and treating influenza in healthy adults","author":"Jefferson","year":"2006","journal-title":"Cochrane Datab. Syst. Rev"},{"key":"B23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1089\/vim.2017.0141","article-title":"Influenza virus: dealing with a drifting and shifting pathogen","volume":"31","author":"Kim","year":"2018","journal-title":"Viral Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1007\/s10096-020-03840-9","article-title":"Influenza and antiviral resistance: an overview","volume":"39","author":"Lampejo","year":"2020","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e1006944","DOI":"10.1371\/journal.pcbi.1006944","article-title":"Model-based analysis of influenza a virus replication in genetically engineered cell lines elucidates the impact of host cell factors on key kinetic parameters of virus growth","volume":"15","author":"Laske","year":"2019","journal-title":"PLoS Comput. Biol"},{"key":"B26","volume-title":"Mathematical and experimental studies of immune response to viral infection (yellow fever, smallpox, influenza)","author":"Le","year":"2014"},{"key":"B27","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1093\/cid\/ciu924","article-title":"Validation of the wild-type influenza A human challenge model H1N1pdmist: an A(H1N1)pdm09 dose-finding investigational new drug study","volume":"60","author":"Memoli","year":"2015","journal-title":"Clin. Infect. Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"104545","DOI":"10.1016\/j.antiviral.2019.104545","article-title":"Antivirals targeting the polymerase complex of influenza viruses","volume":"169","author":"Mifsud","year":"2019","journal-title":"Antiviral Res"},{"key":"B29","first-page":"2","article-title":"A narrative review of influenza: a seasonal and pandemic disease","volume":"42","author":"Moghadami","year":"2017","journal-title":"Iran. J. Med. Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"020421","DOI":"10.7189\/jogh.09.020421","article-title":"Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the glamor project","volume":"9","author":"Paget","year":"2019","journal-title":"J. Global Health"},{"key":"B31","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3389\/fmed.2019.00109","article-title":"Drugs for influenza treatment: is there significant news?","volume":"6","author":"Principi","year":"2019","journal-title":"Front. Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/jac\/dkq014","article-title":"Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir","volume":"65","author":"Reddy","year":"2010","journal-title":"J. Antimicrob. Chemother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/13543784.2019.1606210","article-title":"Investigational antiviral therapies for the treatment of influenza","volume":"28","author":"Yang","year":"2019","journal-title":"Expert Opin. Investig. Drugs"}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.631211\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,19]],"date-time":"2022-12-19T04:54:08Z","timestamp":1671425648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2021.631211\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":34,"alternative-id":["10.3389\/fmicb.2021.631211"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2021.631211","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.11.13.20231357","asserted-by":"object"}]},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]},"article-number":"631211"}}